Donor cell leukemia (DCL) is a rare but serious complication following allo-SCT. Although the etiology of DCL is not well understood, DCL oncogenesis is probably a multifactorial process involving the convergent interplay of different influences. Proposed mechanisms include preleukemic potential in donor cells, replicative stress, impaired immune surveillance and defective marrow microenvironment. Although case numbers remain small, there has not been a consistent chromosome abnormality identified to date, with a normal karyotype being demonstrated in approximately one third of the reported cases. 1 The use of chemotherapy for treatment of DCL can induce remissions but the treatment-related mortality is high because of a prior transplant. The optimal treatment strategy for DCL patients is unclear. Some researchers recently reported cases of DCL following cord blood transplantation (CBT), whereas its clinical features and pathogenesis remain to be fully elucidated.
2 --7 Here, we report a successful case of second CBT in a patient with cord blood donor cell-derived AML harboring a FLT3 internal tandem duplication (FLT3-ITD) and an NPM1 mutation.
Previously, we reported the case of a female enteropathy-type T-cell lymphoma (ETCL) patient; the immunophenotype was CD3 þ , CD7 þ , CD8 þ , CD56 þ and partially positive for granzyme B. She received CBT from a two-Ag-mismatched unrelated female donor in PR after chemotherapy. STR analysis performed on day þ 29 showed complete donor-type engraftment. She developed local relapse of ETCL on day þ 44, but achieved sustained CR after stopping tacrolimus. 8 Eighteen months after CBT, blasts suddenly appeared in the peripheral blood. There were no signs suggesting recurrence of ETCL. BM examination disclosed 97.2% blasts, most of which were negative for myeloperoxidase and positive for fluoride-inhibitable nonspecific esterase; the immunophenotype was CD4
þ , HLA-DR þ and partially positive for CD13, CD14 and CD56. No apparent dysplastic changes were seen in the BM specimens. STR of leukemic cells was identical with that of the first donor ( Figure 1a ). On the basis of these findings, donor cell-derived acute monoblastic leukemia (FAB M5a) was diagnosed. Karyotype analysis of the BM cells was 46, XX and rearrangement of MLL gene was not detected by FISH analysis. A FLT3-ITD mutation was detected by PCR and confirmed by DNA sequencing (Figures 2a  and b ). An NPM1 exon 12 mutation was detected by DNA sequencing (Figure 2c ). The FLT3-ITD and NPM1 mutations were not identified in the cord blood cells of the first donor. The patient achieved CR following first induction chemotherapy with cytarabine and idarubicin. There were no FLT3-ITD and NPM1 mutations detected in BM cells of the patient at remission (Figure 2a and data not shown). Considering the poor prognosis of DCL, we intended to perform second allo-SCT. A donor search within the Japan Marrow Donor Program indicated that there was no suitable donor available. After written informed consent was obtained, we decided to perform second CBT from an unrelated male donor after two cycles of high-dose Ara-C-based consolidation chemotherapy. The number of infused cells before cryopreservation was 3.51 Â 10 7 nucleated cells/kg, which comprised 4.3 Â 10 4 CD34 þ cells/kg. The patient and the second donor had two Ag mismatches and the first and second donor had three Ag mismatches at HLA-A, -B, -C, and -DRB1. The conditioning regimen was the same as in the first CBT, including fludarabine, melphalan, and TBI. 8 GVHD prophylaxis was tacrolimus. G-CSF was started on day þ 1. Engraftment was confirmed on day þ 18 without significant regimen-related toxicity. STR analysis performed on day þ 30 showed complete second donor-type engraftment (Figure 1b) . The patient is currently alive with a sustained CR showing a good performance status at the most recent follow-up 36 months after the second CBT without any signs of chronic GVHD. Cord Blood Bank has not received any reports of leukemia development in the first donor now aged 7 years.
A total of 13 case reports of DCL following CBT has been published since the initial submission of this manuscript.
Interestingly, all but one case of DCL following CBT were myeloid malignancy including AML in eight cases, although there is a higher incidence of ALL in childhood. To our knowledge, there have not been any reports of long-term survival after donor cellderived AML following CBT. Although the role of second allo-SCT for DCL following CBT is uncertain, there is some evidence in DCL involving other donor sources. In a recent review of DCL, at least 27 of 47 (57%) DCL patients were reinduced into CR with salvage chemotherapy with a median OS of 32.8 months.
1 Most of the cases achieving long-term remission received second SCT from an alternative donor, although durable responses to salvage chemotherapy were achieved without SCT in a few cases. Although a longer follow-up period is required to confirm that our patient will not develop DCL again, the promising clinical course of this patient suggests that second CBT for DCL following CBT is feasible. FLT3-ITD and NPM1 mutations are the most common mutations in adult primary AML but are quite uncommon in infant AML. 9, 10 The epidemiologic data suggest that the risk of acquiring them in a myeloid stem/progenitor cell is cumulative. To date, there have not been any reported cases of DCL harboring FLT3-ITD or NPM1 mutations. In our case, her donor cell-derived AML is biologically more similar to primary de novo AML than secondary AML after MDS, as there was no apparent MDS phase before AML. Although the precise mechanism remains unclear, the FLT3-ITD and the NPM1 mutation in her donor cell-derived AML probably occurred during a multistep process of leukemogenesis like those in primary AML and may have evolved in a period as short as 18 months due to replicative stress on the donor cells and impaired marrow microenvironment. In primary AML patients, particularly those with normal karyotype, FLT3-ITD and NPM1 mutations represent unfavorable and favorable prognoses, respectively, and identification of those mutations would help to determine therapeutic options including allo-SCT. Further studies as well as the accumulation of more cases are needed to determine the pathogenesis and the prognostic significance of FLT3-ITD and NPM1 mutations in donor cell-derived AML. 
